Kornimate/medical-research-clean huggingface dataset:
development of urologic registry for personalized medicine in patients with urological malignancy by analyzing circulating tumor dna

Conditions: Prostate Cancer; Renal Cell Cancer; Bladder Cancer; Ureter Cancer

Summary: urological malignancies such as prostate cancer and renal cell cancer in korean population have been increased due to the aged population and the westernized lifestyles. with the advancement of sequencing technologies, use of genetic mutation profiles in cancer detection and progression has been increased. however, use of circulating tumor dna in urological malignances have been limited and few studies have been reported. therefore, we tried to evaluate the usefulness of circulating tumor dna in detection and monitoring of urological malignancies in korean population. this study aims to use circulating tumor dna in plasma and urine for the diagnosis, disease progression monitoring and therapeutic response evaluation. this study plan includes building big databases for circulating tumor dna of urological malignancies in korean population and to develop optimized circulating tumor dna platform.


Eligibility criteria:
inclusion criteria: * 1. patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer) * 2. patients who have undergone surgeries due to urological malignancies in severance hospital, sinchon from 2019.12 and 2029.11 * 3. those who agree to give permission to use their human source information - 4. those who agree with this study exclusion criteria: * 1. those who do not agree with this study * 2. vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
perceptions of ophthalmologists regarding contemporary presbyopia management.

Conditions: Presbyopia

Summary: different attitudes and perceptions are encountered concerning contemporary presbyopia management. exploration of ophthalmologists' attitudes on diagnostic and therapeutic management of presbyopia is essential for the development of disease management interventions by the hellenic ministry of health and welfare. within this context, greek ophthalmologists' perceptions on presbyopia will be explored by means of a custom questionnaire.

different attitudes and perceptions are encountered concerning contemporary presbyopia management. exploration of ophthalmologists' attitudes on diagnostic and therapeutic management of presbyopia is essential for the development of disease management interventions by the hellenic ministry of health and welfare. within this context, greek ophthalmologists' perceptions on presbyopia will be explored by means of a custom questionnaire (depreper31).

Eligibility criteria:
inclusion criteria: * valid license to practice ophthalmology in european union. * adequate literacy of greek language. exclusion criteria: * pediatric ophthalmologist.

Keywords: presbyopia, disease management, ophthalmologist, attitudes
trial on the evaluation of pylorus-ring in pancreaticoduodenectomy

Conditions: Pancreatic Cancer; Bile Duct Cancer; Ampullary Cancer; Duodenal Cancer; Pancreatitis

Summary: the purpose of this study is to clarify whether resecting pylorus-ring decreases delayed gastric emptying after pancreaticoduodenectomy and improves postoperative quality of life (qol).

the purpose of this study is to clarify whether resecting pylorus-ring decreases delayed gastric emptying after pancreaticoduodenectomy and improves postoperative quality of life(qol)compared with preserving pylorus-ring. delayed gastric emptying after pancreaticoduodenectomy are important to affect the postoperative course and qol. however, there is no report that demonstrates the postoperative course between resecting pylorus-ring and preserving pylorus-ring. we conducted a prospective randomized trial on 130 patients who underwent pancreaticoduodenectomy comparing resecting pylorus-ring and preserving pylorus-ring. the primary endpoint was defined as the decrease of delayed gastric emptying. the secondary endpoints were qol, mortality and morbidity, including pancreatic fistula, intra-abdominal hemorrhage, and intra-abdominal abscess. patients were recruited into this study before surgery, on the basis of whether pancreatic head resection was anticipated at wakayama medical university hospital(wmuh) for pancreatic head and periampullary disease, and appropriate informed consent was obtained. exclusion criteria was 1) patients with severe complications which were possible to prolong hospital stay, 2) patients who were diagnosed inadequacy for this study by a physician, 3) patients with a previous gastric resection, and 4) patients without an informed consent.

Eligibility criteria:
inclusion criteria: * on the basis of whether pancreatic head resection was anticipated at wmuh for pancreatic head and periampullary disease, and appropriate informed consent was obtained. exclusion criteria: * patients with severe complications which were possible to prolong hospital stay * patients who were diagnosed inadequacy for this study by a physician * patients who could not be placed a pancreatic stent tube * patients without an informed consent.

Keywords: pylorus-preserving pancreaticoduodenectomy pylorus-resecting pancreaticoduodenectomy randomized controlled trial delayed gastric empty quality of life
clinical efficacy of a 3d foot scanner for the therapeutic footwear fitting

Conditions: Diabetic Foot; Orthopedic Disorder; Foot Ankle Injuries

Summary: patients with diabetes at high risk of ulceration require a perfect fitting shoe to avoid high shear and pressure forces. neuropathy skews sensory perceptions and can alter the proper selection of the therapeutic footwear. the aims of study were to evaluate the ability of high-risk patients with diabetes in remission to select the proper therapeutic footwear and to validate a novel 3d foot scanner app for selecting the proper fitting therapeutic footwear.

a randomized controlled clinical trial in 30 patients with a previous healed diabetic foot ulcer. after parallel randomization (1:1) patients will be enrolled into two different groups: 1. patients that will acquire the therapeutic footwear size and model according to aesthetic preferences; 2. patients that will acquire a specific size and model according to result of a novel mobile app 3d feet scan (smart-fitting by podiapp - podartis s.r.l unipersonale-crocceta del montello (tv), italy). validation of proper therapeutic footwear fitting will be performed by a specialized podiatrist after acquisition of shoes in both groups. therapeutic footwear will be recommended to change when following ill fitting reason been found: excessive length or tight, or compromise with toes

Eligibility criteria:
inclusion criteria: * high risk patients according to the international working group diabetic foot guidelines (iwgdf-risk 3). * healed diabetic foot ulcer at the moment of inclusion. * capability to walk autonomously without walking aids. * diabetic peripheral neuropathy. exclusion criteria: * major amputation in the contralateral limb (below or above the knee).

Keywords: prevention therapeutic footwear new technologies
tradipitant in treatment-resistant pruritus associated with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the united states in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * male and non-pregnant, non-lactating female subjects aged 18 - 65 years (inclusive) * diagnosed with atopic dermatitis * suffering from chronic pruritus with pruritus being actively present exclusion criteria: * chronic pruritus due to condition other than atopic dermatitis (ad) * participation in a previous tradipitant (ly686017 or vly-686) trial * anyone affiliated with the site or sponsor and/or anyone who may consent under duress * any other sound medical reason as determined by the investigator including any condition which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance or may confound study results

Keywords: eczema chronic pruritus
uncontrolled, open label, pilot and feasibility study of niacinamide in polycystic kidney disease

Conditions: Polycystic Kidney Disease

Summary: the goal of this pilot study is to evaluate the feasibility of administering niacinamide to patients with autosomal dominant polycystic kidney disease, to develop methods to assess the biological efficacy of niacinamide, and to perform a preliminary exploration of its clinical effect on kidney cyst growth and kidney function.

niacinamide is a form of vitamin b3. vitamin b3 is found in many foods including yeast, meat, fish, milk, eggs, green vegetables, beans, and cereal grains. recent studies in mice have shown that niacinamide, at high doses, may slow kidney cyst growth from polycystic kidney disease (pkd). by doing this study, the researchers will determine if a larger, long-term study to test whether niacinamide slows progression of pkd is justified.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of autosomal dominant polycystic kidney disease * egfr \> 90ml/min/1.73m2 as determined from the serum creatinine by the ckd-epi equation * ability to give informed consent in english exclusion criteria: * history of liver disease or abnormal liver function test * heavy alcohol intake * chronic diarrhea or malabsorption syndrome * thrombocytopenia * hypophosphatemia * pregnancy or lactation or plan to become pregnant during the study * treatment with anti-epileptic drugs * treatment with tolvaptan, current or within 2 months prior to screening * participation in another interventional trial currently or within 30 days prior to screening * partial or total nephrectomy or renal cyst reduction (including aspiration) done \<1 year ago * cardiac pacemaker * presence of magnetic resonance-incompatible metallic clips (e.g. clipped cerebral aneurysm) * body weight \>159 kg (350 lbs) or untreatable claustrophobia

Keywords: pkd niacinamide vitamin b3 vitamin b
prostate tissue biobank

Conditions: Prostate Cancer; Genetic Predisposition

Summary: prostate cancer is also the most common cancer in men with inherited pathogenic variants in brca1 and brca2. beyond brca1/2, other genes are known to increase the risk of prostate cancer, including atm, tp53 and hoxb13. we have shown that 5% of men diagnosed with prostate cancer localized to their prostate gland and up to 10-15% of patients with metastatic prostate cancer gland are carriers of an inherited gene mutation. the prostate tissue biobank is a prospective study which aims to create a biorepository of prostate tissue samples from prostate biopsies and prostatectomies and matched germline dna from pathogenic mutation carriers in addition to age-matched control samples. our primary goal is to investigate prostate cancer development and treatment response in carriers of germline dna repair mutations, as compared to non-carrier controls.


Eligibility criteria:
inclusion criteria: carriers (group 1): 1. confirmed pathogenic or likely pathogenic variant in a known prostate cancer risk gene. 2. patients undergoing prostate biopsies as a part of their prostate cancer screening or biopsy or prostatectomy due to a diagnosis of prostate cancer controls (group 2): 1. patients undergoing prostate biopsies as a part of their prostate cancer screening or biopsy or prostatectomy due to a diagnosis of prostate cancer exclusion criteria: * n/a
clinical pathways and patients' attitudes in acute low back pain

Conditions: Acute Low Back Pain

Summary: in france the prevalence of low back pain is 70 to 80 %. it's the leading cause of health expenditure in europe and costs 900 million euros per year to health insurance in france. this is the second reason to consult a general practitioner. acute low back pain is defined as low back pain lasts less than 6 weeks. it represents 60 to 70 % of low back pain but only 20% of the costs induced by low back pain in general. in fact, acute low back pain often heals spontaneously. risk factors for acute low back pain and risk factors for chronic low back pain have been the subject of many publications. they remain very difficult to prevent in practice because of their multiplicity. preventing acute low back pain is part of the prevention of chronic low back pain. patient care management of low back pain is well codified and consensual in the various international recommendations. however, their application is sometimes very disparate and bad habits on both patients and professionals persist. advices recommended in the case of low back pain are widely disseminated but their applications are little studied. in 2017, in france, health insurance started a "back pain" prevention campaign with the objective of raising awareness of good attitudes in the event of back pain. it made an initial assessment of the different knowledges concerning spinal pain in the general population but also in the medical population with the aim of improving them. it appears that number of patients would not consult physician in this case. the many proposals of care and the diversity of medical professionals, paramedics and other stakeholders, proposing to cure low back pain form as many different clinical pathways. use of alternative or unconventional medicines is poorly assessed. in this context, it seems relevant to evaluate patient clinical pathways and patients' attitudes.

the aim of the study is to explore patient clinical pathways and patients' attitudes in acute low back pain

Eligibility criteria:
inclusion criteria : * men and women * aged between 18 and 65 years old * living in france * to have ever had an acute low back pain * accepting to participate in the study exclusion criteria : - over 65 or under 18 years old

Keywords: acute low back pain low back pain clinical pathway
glaucoma after congenital and infantile cataract surgery

Conditions: Glaucoma; Congenital Cataract

Summary: pediatric patients who have undergone surgery for congenital or infantile cataracts have a risk of developing suspected glaucoma and glaucoma, but the current evidence does not address our understanding of the incidence and associated risk factors of suspected glaucoma/glaucoma for application in clinical standard care. therefore, this study investigated the incidence of and risk factors for suspected glaucoma/glaucoma in patients who have undergone surgery for congenital/infantile cataracts.

a prospective longitudinal cohort study of pediatric patients who underwent surgery for congenital/infantile cataracts between january 2011 and december 2021 was performed.

Eligibility criteria:
inclusion criteria: * a diagnosis of congenital/infantile cataracts without any surgical intervention; * age younger than 10 years; * cataract surgery performed at the zhongshan ophthalmic center after enrollment exclusion criteria: * a preoperative iop above 21 mm hg; * the presence of any preoperative sign of glaucoma, such as corneal enlargement, corneal clouding, excessive optic nerve cupping, or a family history of glaucoma; * the presence of ocular trauma or other abnormalities, such as microcornea, microphthalmia, persistent hyperplastic primary vitreous, peters anomaly, congenital aniridia, marfan syndrome, lens dislocation, retinitis pigmentosa, high myopia, fundus lesions, rubella, and lowe syndrome.
study of the effect on clinical outcomes using secure text messaging

Conditions: Congestive Heart Failure; Diabetes; Renal Failure; Copd

Summary: in this study, the investigators will conduct a randomized, controlled trial to evaluate the impact of offering mobile secure text messaging on clinical outcomes.

inpatient health care providers such as physicians and nurses spend up to one-third of their time communicating with other health care providers. many of these communications have shifted mediums from handwritten notes and face-to-face conversations to phone calls and paging systems. more recently the rapid adoption of smartphones has led to the use of mobile-enabled technologies using smartphones such as text messaging and email. while these technologies may offer ease and fit better within the clinical workflow, they often send patient information through unsecure cellular or internet connections. mobile secure text messaging may address these issues by encrypting data and allowing for asynchronous or synchronous communication between individual providers or groups of providers. in this study, the investigators will conduct a randomized, controlled trial to evaluate the impact of offering mobile secure text messaging on clinical outcomes.

Eligibility criteria:
inclusion criteria: * admission to one of the hospital floors or services in the study at the hospital of the university of pennsylvania exclusion criteria: * discharges against medical advice * discharges to hospice

Keywords: mhealth text messaging secure text messaging communication
once-a-day immunosuppression(cisecon_a_day)

Conditions: Chronic Renal Disease

Summary: the objective of this study is to assess the efficacy and safety and immunosuppressant therapy barrier scale (itbs) of once daily immunosuppressant maintenance therapy in patients who had kidney transplantations earlier.

this is a 6-month, single-arm, multi-center, open-label, continuous cohort study. 160 subjects who had kidney transplantations at least 3 months earlier will participate in the study. all enrolled subjects will discontinue the existing tacrolimus preparations for 6 months from enrollment and be converted to extended release tacrolimus at a biologically equivalent dose. they will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with sirolimus and observed.

Eligibility criteria:
inclusion criteria: * men or women at the age of 20 to 65 who had kidney transplantations at least 3 months ago. * recipients of kidney transplantations from a deceased / cadaveric donor, non-heart beating cadaveric donor / organ donor after cardiac death, or non-blood related or blood related live donor. * patients being treated with tacrolimus or extended release tacrolimus as the existing immunosuppressant maintenance therapy. * able and willing to give informed consent to study participation, having signed the informed consent form according to appropriate procedures, and capable of participating in the study by making visits according to study plans. exclusion criteria: * hiv, hbsag, or anti-hcv test positive patients or having received kidney transplantations from an hiv, hbsag, or anti-hcv test positive donor. * history of severe allergies or hypersensitivities to drugs used in the study or other drugs with a similar chemical structure requiring acute (within the past 4 weeks) or chronic treatment. * having received other investigational product within 30 days prior to enrollment into this study. * women of childbearing potential who plan to become pregnant, pregnant and/or lactating women, women who do not intend to use effective contraceptives. * having uncontrolled diseases or medical conditions requiring continuous treatment. * history of alcohol or drug addiction within the past 3 months or incapable of appropriate communications due to reasons such as mental illness. * absolute neutrophil count \<1,500/mm3 or leukocyte count \<2,500/mm3 or platelet count \<75,000/mm3 at screening or severe metabolic disorders (including functional disorders). * having experienced the following condition within the past 1 month: * serum creatinine \> 2.0 mg/dl more than twice. * 24 hr urine protein≥750 mg/day * diagnosed with or treated for a rejection reaction or an infection or hospitalized due to other medical reasons.

Keywords: once
sargramostim with ipilimumab containing therapy in patients with solid tumors

Conditions: Solid Tumor; Solid Tumor, Adult

Summary: this open label, randomized study will evaluate safety and tolerability of sargramostim when combined with an ipilimumab-containing regimen received as part of standard of care therapy. the study will evaluate 2 sargramostim administration schedules. patients will be randomized 1:1 to the sargramostim administration schedules and stratified based on planned dose of ipilimumab (1 mg/kg, 3 mg/kg). sargramostim will be administered for the first 12 weeks following the assigned treatment schedule or until disease progression, intolerable toxicity, consent withdrawal, pregnancy, or death, whichever comes first. checkpoint inhibitor therapy will be administered in accordance with institutional standard of care guidelines, at the investigator's discretion. patients will be followed up for to 24 weeks following end of sargramostim treatment for safety, efficacy, and survival.


Eligibility criteria:
inclusion criteria: * adult patients with solid tumors that will start an ipilimumab-containing therapy (with or without anti-pd-1, such as nivolumab) as part of standard of care in approved ipilimumab indication * recovery from any toxicities related to prior therapies * ability and willingness to self-administer or have a caregiver administer a sc injection of sargramostim * women of child-bearing potential willing to use birth control exclusion criteria: * recent radiation therapy for cancer that has spread to bones or to the brain * history of a severe reaction to prior immune checkpoint inhibitors * pleural or pericardial effusion, or history of recurrent pleural or pericardial effusion. * heart rhythm with symptoms within the last 12 months * known or suspected intolerance or hypersensitivity to sargramostim or any product component or diluent * use drugs that can suppress the immune system * women who are pregnant or breastfeeding * live virus vaccine within 28 days prior to study treatment and for 4 weeks after study treatment. * have other active cancers * participation in another clinical trial * any other medical condition or laboratory abnormality that would put patient at risk or confound interpretation of trial results